Clinical Trial

JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL

Name: JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL — clinical trial record (NCT07406178)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of JY509 universal NK cell injection.

Trial Details

NCT Number	NCT07406178
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Relapsed/Refractory Pediatric B-ALL
Enrollment	18 participants
Start Date	2026-01-20
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-12